BMRN BioMarin Pharmaceutical Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save to watchlist or track a position.
BMRN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$56.21
Analyst Target
$90.74
+61.4%
Upside
52W High
$73.51
52W Low
$50.76
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$10.8B
P/E
21.29
ROE
9.1%
Profit margin
16.8%
Debt/Equity
0.1
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
72%
BMRN exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust accounting strength, though the absence of an Altman Z-Score limits distress risk assessment. The stock trades above its Graham Number of $43.28 at $56.21, suggesting a moderate premium, while forward P/E of 10.78 implies improving earnings expectations. Despite solid gross margins and low leverage, negative operating margin and volatile earnings growth—especially recent YoY EPS decline of 86.8%—raise sustainability concerns. Analysts are bullish with a $90.74 target, but insider activity is neutral and price performance has been weak over 3Y and 5Y horizons.
Key Strengths
Piotroski F-Score of 8/9 indicates excellent financial health and strong earnings quality
Exceptionally high gross margin of 81.32% reflects pricing power and low cost of goods in biotech model
Very low Debt/Equity ratio of 0.10 signals conservative capital structure and minimal solvency risk
Current Ratio of 4.83 and Quick Ratio of 2.84 demonstrate superior short-term liquidity
Analyst consensus recommendation is 'buy' with a high target price of $90.74 implying 61% upside
Key Risks
Operating margin is negative at -6.02%, indicating core operations are not yet profitable
YoY EPS growth down 86.8% and most recent Q/Q EPS down 91.7% show severe earnings deterioration
Forward earnings volatility evident in recent estimate misses: 2 of last 4 quarters missed expectations
Long-term price performance is weak: -50.6% over 3Y and -36.8% over 5Y despite strong recent quarters
Insider sentiment is neutral with zero buy/sell transactions in last 6 months, suggesting lack of conviction
AI Fair Value Estimate
Based on comprehensive analysis
$43.28
-23.0% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
52
Moderate
58
52
64
88
0
AI Verdict
Cautiously optimistic with strong fundamentals offset by earnings volatility and valuation premium
Key drivers: High Piotroski score and strong liquidity, Negative operating margin and declining EPS, Valuation above Graham Number but below analyst target, Biotech sector volatility and lack of dividend support
Confidence
75%
Value
58/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 10.78 is below current P/E of 21.29, suggesting earnings recovery priced in
- Price/Sales of 3.49 is reasonable for biotech growth firm
Watchpoints
- Current price ($56.21) trades above Graham Number ($43.28), indicating overvaluation on defensive metrics
- PEG Ratio unavailable, limiting growth-adjusted valuation analysis
Future
52/100
Ref Growth rates
Positives
- Forward P/E implies expectation of earnings rebound
- Revenue growth stable at 4.10% YoY in a capital-intensive sector
Watchpoints
- YoY EPS growth down 86.8%, most recent Q/Q EPS down 91.7%
- Earnings growth (YoY) data missing, increasing uncertainty
Past
64/100
Ref Historical trends
Positives
- Historical earnings surprises show strong beats in prior years (e.g., +107.6% in 2021)
- Long-term revenue growth trend has been positive
Watchpoints
- Recent quarters show declining reliability: 2 of last 4 missed estimates
- 52-week low of $50.76 is below current price, indicating recent bearish momentum
Health
88/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 8/9 indicates strong financial health across profitability, leverage, and operating efficiency
- Debt/Equity of 0.10 shows minimal financial leverage
- Current and Quick Ratios well above 1, indicating excellent liquidity
Watchpoints
- Altman Z-Score not available, limiting distress risk modeling
- Operating margin negative at -6.02%, a red flag despite high gross margin
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid (Dividend Yield: N/A, Payout Ratio: 0.00%)
- Dividend Strength score is 0/100, offering no income support
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$56.21
Analyst Target
$90.74
Upside/Downside
+61.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BMRN and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical Inc.
Primary
|
-36.8% | -50.6% | -9.6% | -4.7% | -6.6% | +3.0% |
|
MOH
Molina Healthcare, Inc.
Peer
|
-12.6% | -36.1% | -32.3% | +4.6% | +17.9% | +5.5% |
|
BAX
Baxter International Inc.
Peer
|
-72.4% | -52.4% | -37.8% | -31.6% | +3.8% | -1.3% |
|
ALGN
Align Technology, Inc.
Peer
|
-70.6% | -48.8% | +2.3% | +24.8% | -16.9% | -5.6% |
|
BIO-B
Bio-Rad Laboratories, Inc.
Peer
|
-47.0% | -22.7% | -10.4% | +26.6% | +0.7% | +0.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
21.29
Forward P/E
10.78
PEG Ratio
N/A
P/B Ratio
1.78
P/S Ratio
3.49
EV/Revenue
3.21
EV/EBITDA
12.5
Market Cap
$10.8B
Profitability
Profit margins and return metrics
Profit Margin
16.82%
Operating Margin
-6.02%
Gross Margin
81.32%
ROE
9.07%
ROA
6.15%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.1
Low debt
Current Ratio
4.83
Strong
Quick Ratio
2.84
Excellent
Cash/Share
$7.69
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-19
$N/A
2025-10-27
$0.12
-64.3% surprise
2025-08-04
$1.44
+39.4% surprise
2025-05-01
$1.13
+18.6% surprise
Healthcare Sector Comparison
Comparing BMRN against 147 companies in the Healthcare sector
(11 bullish, 53 neutral, 83 bearish)
P/E Ratio
21.29
This Stock
vs
164.49
Sector Avg
-87.1%
(Discount)
Return on Equity (ROE)
9.07%
This Stock
vs
-52.77%
Sector Avg
-117.2%
(Below Avg)
Profit Margin
16.82%
This Stock
vs
-20.75%
Sector Avg
-181.1%
(Weaker)
Debt to Equity
0.1
This Stock
vs
6.16
Sector Avg
-98.4%
(Less Debt)
Revenue Growth
4.1%
This Stock
vs
135.79%
Sector Avg
-97.0%
(Slower)
Current Ratio
4.83
This Stock
vs
3.36
Sector Avg
+43.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical Inc.
|
NEUTRAL | $10.8B | 21.29 | 9.1% | 16.8% | $56.21 | |
|
MOH
Molina Healthcare, Inc.
|
BEARISH | $10.37B | 11.79 | 19.7% | 2.1% | $191.4 | |
|
BAX
Baxter International Inc.
|
BEARISH | $10.2B | - | -4.7% | -3.1% | $19.84 | |
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $11.78B | 29.07 | 10.4% | 10.2% | $164.23 | |
|
BIO-B
Bio-Rad Laboratories, Inc.
|
BEARISH | $9.79B | - | -9.5% | -26.4% | $312.75 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-20 | RAMCHANDANI RASHMI VIRENDRA | Officer | Stock Award | 25,610 | - |
| 2025-08-01 | CLARK IAN THORNTON | Director | Stock Award | 7,000 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
23 analysts
Canaccord Genuity
2026-01-20
Hold
Buy
Truist Securities
2025-12-23
Buy
Buy
HC Wainwright & Co.
2025-12-22
Neutral
Neutral
Leerink Partners
2025-12-03
Outperform
Market Perform
Stifel
2025-11-06
Buy
Hold
Bernstein
2025-11-03
Outperform
Outperform
Truist Securities
2025-10-28
Buy
Buy
Wells Fargo
2025-10-28
Overweight
Overweight
Stifel
2025-10-28
Buy
Buy
Barclays
2025-10-28
Overweight
Overweight
Past News Coverage
Recent headlines mentioning BMRN from our newsroom.
Newest → oldest
No matching news yet.